Posts Tagged Ann Falsey

Since last July, the University of Rochester Medical Center has been a leader in the US national clinical trials for the COVID vaccine developed by AstraZeneca and the University of Oxford.

An interim analysis of study data from a coronavirus vaccine being developed by Pfizer and BioNTech indicates that the vaccine is highly effective in preventing COVID-19. Researchers and volunteers in Rochester have been involved in the testing of the vaccine since May, when the first human studies were launched, and technologies used in the development of the vaccine can trace their origins to decades of infectious disease research conducted at the University of Rochester Medical Center.

The Medical Center’s Ann Falsey and Angela Branche, both with the Vaccine and Treatment and Evaluation Unit, are leading an NIH-sponsored clinical trial of remdesivir in the treatment of COVID-19.

Researchers at the University of Rochester’s New York Influenza Center of Excellence, one of five such centers of excellence in the world, are launching a new study to determine if and when a person could be re-infected with the novel coronavirus and whether some people have pre-existing immunity.

Researchers at the University of Rochester Medical Center are evaluating whether an antiviral drug is effective and safe as a treatment for hospitalized adults diagnosed with COVID-19.